<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Viloxazine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Viloxazine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Viloxazine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="131244" href="/d/html/131244.html" rel="external">see "Viloxazine: Drug information"</a> and <a class="drug drug_patient" data-topicid="138733" href="/d/html/138733.html" rel="external">see "Viloxazine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F55676198"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with attention-deficit hyperactivity disorder (ADHD) treated with viloxazine than in patients treated with placebo. Closely monitor all viloxazine-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55700934"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Qelbree</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55676310"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Norepinephrine Reuptake Inhibitor, Selective</span></li></ul></div>
<div class="block dop drugH1Div" id="F55696187"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: Oral: Initial: 100 mg once daily; may titrate in 100 mg increments at weekly intervals based on response and tolerability; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: Oral: Initial: 200 mg once daily; may increase to 400 mg after 1 week based on response and tolerability; maximum daily dose: 400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral: Initial: 200 mg once daily; may titrate in 200 mg increments at weekly intervals based on response and tolerability; maximum daily dose: 600 mg/<b>day</b>.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55696188"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate impairment (eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>):</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe impairment (eGFR &lt;30 ml/minute/1.73 m<sup>2</sup>):</i> Oral: Initial dose: 100 mg once daily; may titrate in 50 to 100 mg increments at weekly intervals based on response and tolerability; maximum daily dose: 200 mg/<b>day</b>.</p></div>
<div class="block dohp drugH1Div" id="F55696189"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F56809474"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="131244" href="/d/html/131244.html" rel="external">see "Viloxazine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder: Oral:</b> Initial: 200 mg once daily; may titrate by 200 mg increments at weekly intervals based on response and tolerability; maximum daily dose: 600 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56809477"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate impairment (eGFR 30 to 89 mL/minute/1.73 m</i>
<i>
<sup>2</sup></i>
<i>):</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>):</i>
<b>Oral:</b> Initial dose: 100 mg once daily; may titrate by 50 to 100 mg increments at weekly intervals based on response and tolerability; maximum daily dose: 200 mg/<b>day</b>.</p></div>
<div class="block doha drugH1Div" id="F56809478"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild to severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block arsc drugH1Div" id="F56165300"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Viloxazine commonly causes<b> increased heart rate </b>and <b>increased diastolic blood pressure</b>. In children, adolescents, and adults, a ≥20 beat per minute increase in heart rate has been observed; tachycardia has also been reported. In adolescents and adults, a ≥15 mm Hg increase in diastolic blood pressure has been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Has not been fully elucidated, but it has been suggested that viloxazine, due to its moderate inhibition of the reuptake of norepinephrine, may increase blood pressure by way of increased norepinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32943948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32943948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (potential risk factor)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with a monoamine oxidase inhibitor (MAOI), or administration within 14 days after MAOI discontinuation. Of note, concomitant use of MAOIs is contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Suicidal ideation</b> and <b>suicidal tendencies</b> have been observed. Other symptoms (eg, insomnia, irritability, depressed mood) may represent precursors to emerging suicidal ideation or behavior, although causality has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; although it has been suggested that the relationship between attention-deficit hyperactivity disorder (ADHD) and suicidal ideation (if one exists) may be related to underlying impulsivity and aggression and/or indirectly mediated by comorbidities such as depression rather than related to medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331','lexi-content-ref-24964928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331','lexi-content-ref-24964928'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with ADHD, regardless of medication use, are often considered to be at higher risk for suicide compared to the general population and typically have an increased prevalence of many psychiatric comorbidities, such as depression, conduct disorder, substance abuse, which are associated with an increased risk of suicide, regardless of medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331','lexi-content-ref-25019647','lexi-content-ref-24964928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331','lexi-content-ref-25019647','lexi-content-ref-24964928'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55678040"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased diastolic blood pressure (13% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Increased Diastolic Blood Pressure table link" class="lexi-table-link" data-table-id="lexi-content-increased-diastolic-blood-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-diastolic-blood-pressure')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Diastolic Blood Pressure</span>, increased heart rate (22% to 34%; tachycardia: 4% [adults])<span class="lexi-table-link-container"> (<a aria-label="Increased Heart Rate table link" class="lexi-table-link" data-table-id="lexi-content-increased-heart-rate" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-heart-rate')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Heart Rate</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Diastolic Blood Pressure" frame="border" id="lexi-content-increased-diastolic-blood-pressure" rules="all">
<caption style="text-align:center;">
<b>Viloxazine: Adverse Reaction: Increased Diastolic Blood Pressure</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Viloxazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Viloxazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">201</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥15 mmHg increase</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg to 600 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">178</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">181</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥15 mmHg increase</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Heart Rate" frame="border" id="lexi-content-increased-heart-rate" rules="all">
<caption style="text-align:center;">
<b>Viloxazine: Adverse Reaction: Increased Heart Rate</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Viloxazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Viloxazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">268</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">262</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">201</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg to 600 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">178</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">181</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥20 beat per minute increase in heart rate at any time point in the clinical trial</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (4% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (including lethargy and sedated state; 6% to 19%), fatigue (4% to 12%), headache (including migraine; 10% to 17%), insomnia (children and adolescents: 2% to 5%; adults: 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: 6% to 7%), constipation (adults: 6%), decreased appetite (5% to 10%), gastroesophageal reflux disease (adults: 2%), vomiting (3% to 6%), xerostomia (adults: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adults: 4%), irritability (2% to 5%), suicidal ideation (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (including nasopharyngitis, pharyngitis, sinusitis; children and adolescents: 7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Weight loss (adolescents)</p></div>
<div class="block coi drugH1Div" id="F55676204"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with or within 14 days of monoamine oxidase inhibitors (MAOI); concomitant use of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F55756515"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause fatigue, lethargy, and sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, driving, operating machinery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Mania/hypomania: Use with caution in patients with bipolar disorder; may induce mixed or manic episode. Patients should be screened for bipolar disorder and risk factors for developing a manic episode prior to treatment (eg, comorbid or history of depressive symptoms; family history of suicide, bipolar disorder, or depression).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55696185"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Viloxazine can increase heart rate and blood pressure. Prior to treatment with medications for attention-deficit hyperactivity disorder (ADHD), the American Heart Association and the American Academy of Pediatrics recommend that all children and adolescents diagnosed with ADHD have a thorough cardiovascular assessment, including patient and family health histories, determination of all medications used (prescribed and over-the-counter), and a physical examination focused on cardiovascular disease risk factors. An ECG is not mandatory but is reasonable to consider prior to stimulant medication therapy. Prompt evaluation and appropriate referral and testing, if warranted, should occur if any cardiac symptoms present (AAP [Wolraich 2019]; AHA [Vetter 2008]).</p></div>
<div class="block foc drugH1Div" id="F55700935"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qelbree: 100 mg, 150 mg, 200 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p></div>
<div class="block geq drugH1Div" id="F55700933"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55724849"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Qelbree Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $14.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $14.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $14.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F55696190"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food; do not cut, chew, or crush capsule. Swallow capsules whole or open and sprinkle entire contents on teaspoonful of pudding or applesauce; consume entire mixture without chewing within 15 minutes for pudding or within 2 hours for applesauce; do not store for future use.</p></div>
<div class="block adm drugH1Div" id="F56809480"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to food; do not cut, chew, or crush capsule. Swallow capsules whole or open and sprinkle entire contents on teaspoonful of applesauce or pudding; consume entire mixture without chewing within 15 minutes for pudding or 2 hours for applesauce; do not store for future use.</p></div>
<div class="block hazard drugH1Div" id="F55769560"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Viloxazine may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F55756519"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F56829748"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F211964s003lbl.pdf%23page%3D21&amp;token=qydRPG2KDqbKIfxLj%2FKhzk8qnVEreLU9ugoS9ClPKX%2BrZijWi0kSv8IZE7G7mr9dqqhU6YNnvF7wRZZo4qcAdJVqk56htP8NPrauCOyjJLDXcYiA9yuUOy%2BS%2FAJICqxW&amp;TOPIC_ID=131245" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf#page=21</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F55676312"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of attention-deficit hyperactivity disorder (ADHD) (FDA approved in ages ≥6 years and adults).</p></div>
<div class="block mst drugH1Div" id="F55756511"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Viloxazine may be confused with vilazodone.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55687600"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), UGT1A9, UGT2B15; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (strong), CYP2D6 (weak), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F55687597"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Agomelatine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Strong) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Asenapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.  Management: Consider alternatives to strong CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Strong) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of CloZAPine.  Management: Reduce the dose of clozapine to one-third of the original dose when adding a strong CYP1A2 inhibitor and monitor patient response closely. Return to the original clozapine dose when the strong CYP1A2 inhibitor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of DULoxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Fenfluramine.  Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP1A2 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Viloxazine may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Selective Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levobupivacaine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP1A2 Inhibitors (Strong) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Melatonin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Viloxazine may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Selective Norepinephrine Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and strong CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 801 mg per day (267 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.  Management: Avoid when possible. If coadministration is necessary, reduce the pomalidomide dose to 2 mg and monitor for increased pomalidomide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Propranolol.  Management: Use a lower initial propranolol dose and be more cautious during propranolol dose titration when combined with strong CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riluzole: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Riluzole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: Viloxazine may increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Viloxazine may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Strong) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Viloxazine may increase the serum concentration of Theophylline Derivatives. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of TiZANidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F55756518"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">High fat meal may increase time to peak concentration by 2 hours.</p></div>
<div class="block pri drugH1Div" id="F55756513"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to viloxazine may cause fetal harm. According to the manufacturer, consider discontinuing viloxazine if pregnancy occurs during treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to viloxazine is ongoing. Health care providers are encouraged to enroll patients exposed to viloxazine during pregnancy in the National Pregnancy Registry for Psychiatric Medications (1-866-961-2388 or https://www.womensmentalhealth.org/preg
                     <span style="text-decoration: underline">)</span>.</p></div>
<div class="block mopp drugH1Div" id="F55696191"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to initiating viloxazine, conduct a thorough physical exam to assess for cardiac disease and assessment of medical history and family history of sudden death or ventricular arrhythmia; patients should receive further evaluation if findings suggest cardiac disease, such as ECG and echocardiogram; promptly conduct cardiac evaluation in patients who develop exertional chest pain, unexplained syncope, or any other symptoms of cardiac disease during treatment (AAP [Wolraich 2019]; AHA [Vetter 2008]).</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should be screened for a personal or family history of suicide, bipolar disorder, and depression prior to initiating viloxazine. Family members and caregivers need to observe pediatric patients daily, especially during the initial few months of therapy or at times of dose changes, for clinical worsening and emergence of suicidal ideation, irritability, agitation, unusual changes in behavior, anxiety, agitation, panic attacks, insomnia, impulsivity, aggressiveness, hostility, akathisia, psychosis, hypomania, and mania. Appearance of such symptoms needs to be immediately reported to health care provider.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood pressure and pulse (baseline, following dose increases, and periodically during treatment); monitor liver enzymes, serum creatinine, GFR. Periodically re-evaluate the long-term usefulness of viloxazine.</p></div>
<div class="block pha drugH1Div" id="F55756520"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Viloxazine blocks the reuptake of norepinephrine. The exact mechanism underlying the beneficial effects of viloxazine for the treatment of attention-deficit hyperactivity disorder (ADHD) has not been fully elucidated. Some data (in vitro) suggest that it appears to inhibit 5-HT<sub>2B</sub> receptor and activate 5-HT<sub>2C</sub> receptor (Yu 2020).</p></div>
<div class="block phk drugH1Div" id="F55756521"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration with a high-fat meal (800 to 1,000 calories) may decrease absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 76% to 82%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by CYP2D6, UGT1A9, and UGT2B15.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~88%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 7.02 ± (4.74 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~5 hours (range 3 to 9 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily renal. Urine: 90%; feces: &lt;1%.</p></div>
<div class="block phksp drugH1Div" id="F55756529"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: After administration of 200 to 400 mg doses, C<sub>max</sub> and AUC concentrations were ~130% to 250% and 60% to 140% higher in pediatric patients 6 to 11 years of age and 12 to 17 years of age, respectively, compared to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Exposure increases can be expected in patients with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216511"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Qelbree</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Qelbree</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.2020">
<a name="HazardousDrugs.2020"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18176331">
<a name="18176331"></a>Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(2):209-218. doi:10.1097/chi.0b013e31815d88b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/18176331/pubmed" id="18176331" target="_blank">18176331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25019647">
<a name="25019647"></a>Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. <i>J Child Adolesc Psychopharmacol</i>. 2014;24(8):426-34. doi:10.1089/cap.2014.0005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/25019647/pubmed" id="25019647" target="_blank">25019647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24964928">
<a name="24964928"></a>Ljung T, Chen Q, Lichtenstein P, Larsson H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. <i>JAMA Psychiatry</i>. 2014;71(8):958-964. doi:10.1001/jamapsychiatry.2014.363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/24964928/pubmed" id="24964928" target="_blank">24964928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qelbree.2021.04">
<a name="Qelbree.2021.04"></a>Qelbree (viloxazine) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed May 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423. doi:10.1161/CIRCULATIONAHA.107.189473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003063">
<a name="22003063"></a>Wolraich M, Brown L, Brown RT, et al: Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022. doi:10.1542/peds.2011-2654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/22003063/pubmed" id="22003063" target="_blank">22003063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32943948">
<a name="32943948"></a>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. <i>J Exp Pharmacol</i>. 2020;12:285-300. doi:10.2147/JEP.S256586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viloxazine-pediatric-drug-information/abstract-text/32943948/pubmed" id="32943948" target="_blank">32943948</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131245 Version 61.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
